Treatment approach in patients with hyperbilirubinemia secondary to liver metastases in gastrointestinal malignancies: a case series and review of literature
Conclusion:
Treatment with oxaliplatin, FP/FA ± moAb is feasible and may derive relevant benefits in patients with severe liver dysfunction caused by GI cancer liver metastases without further options of drainage.
Source: Therapeutic Advances in Medical Oncology - Category: Cancer & Oncology Authors: Quidde, J., Azemar, M., Bokemeyer, C., Arnold, D., Stein, A. Tags: Original Research Source Type: research
More News: Bilirubin | Cancer | Cancer & Oncology | Eloxatin | Gastroenterology | Liver | Urology & Nephrology